BiotechTube

17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle) + Tibolone (Livial)

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Vasomotor Symptoms

Conditions

Vasomotor Symptoms

Trial Timeline

Feb 1, 2006 → Dec 1, 2009

NCT ID
NCT00472004

About 17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle) + Tibolone (Livial)

17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle) + Tibolone (Livial) is a approved stage product being developed by Pfizer for Vasomotor Symptoms. The current trial status is completed. This product is registered under clinical trial identifier NCT00472004. Target conditions include Vasomotor Symptoms.

What happened to similar drugs?

0 of 13 similar drugs in Vasomotor Symptoms were approved

Approved (0) Terminated (0) Active (13)
🔄fezolinetant + placeboAstellas PharmaPhase 3
🔄DVS-233 SRPfizerPhase 3
🔄Bazedoxifene/Conjugated EstrogenPfizerPhase 3
🔄desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + Placebo + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained releasePfizerPhase 3
🔄desvenlafaxine succinate (DVS) SR + PlaceboPfizerPhase 3
🔄Elinzanetant (BAY3427080) + PlaceboBayerPhase 3
🔄Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg + Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mgBayerPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00472004ApprovedCompleted

Competing Products

20 competing products in Vasomotor Symptoms

See all competitors
ProductCompanyStageHype Score
fezolinetant + placeboAstellas PharmaPhase 3
40
Raloxifene + medroxyprogesterone acetate + estrogen + 17 beta estradiolEli LillyPhase 2
35
esomeprazole + placeboAstraZenecaPre-clinical
26
MK-6913 + 17-β estradiol + Placebo to MK-6913 + Placebo to 17-β estradiol + MK-6913 25 mgMerckPhase 2
27
Erenumab + PlaceboAmgenPhase 1
29
DVS-233 SRPfizerPhase 3
40
Bazedoxifene/Conjugated EstrogenPfizerPhase 3
40
desvenlafaxine succinate sustained release (DVS SR)PfizerPhase 1
29
desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + Placebo + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained releasePfizerPhase 3
40
desvenlafaxine succinate (DVS) SR + PlaceboPfizerPhase 3
40
Treatment A + Treatment B + Treatment CBayerPhase 1
26
Elinzanetant (BAY3427080) + PlaceboBayerPhase 1
26
Elinzanetant (BAY3427080) + PlaceboBayerPhase 3
41
Elinzanetant (BAY3427080) treatment A + Elinzanetant (BAY3427080) treatment BBayerPhase 1
26
Elinzanetant (BAY3427080)BayerPhase 1
26
Moxifloxacin + Elinzanetant (BAY3427080) + PlaceboBayerPhase 1
26
Elinzanetant (BAY3427080) + Dabigatran etexilateBayerPhase 1
26
Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg + Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mgBayerPhase 3
37
BAY3427080BayerPhase 1
26
Elinzanetant (BAY3427080) + RosuvastatinBayerPhase 1
26